A double-blind randomized trial on subendometrial injection of vasopressin to control bleeding in postpartum hysterectomy due to abnormally invasive placenta

What Was Tested

Researchers studied Vasopressin in this randomized controlled trial publication.

To investigate the effect of subendometrial vasopressin injection in patients with abnormally invasive placenta (AIP), who underwent cesarean section and hysterectomy.

Who Took Part

By PubMed's age tags, the people studied were adults, women only.

This randomized double-blinded clinical trial was conducted on pregnant women diagnosed with AIP grade 4 and 5 by ultrasonography during cesarean section.

Vasopressin and placebo were injected subendometrially 1 cm medial to the uterine vessels into the lower uterine segment.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Because people in this Vasopressin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Vasopressin.

Some participants received a placebo instead of Vasopressin, giving a reference point.

The exclusion criteria include presence of myocardial infarction, cardiomyopathy, congestive heart failure, uncontrolled hypertension, chronic obstructive pulmonary disease, pelvic malignancy.

The outcome of the study was total quantitative blood loss during the cesarean section.

The researchers estimated blood loss by measuring the blood volume in one of the suction bottles with addition for weight changes of mops, pads, and soaked linen savers.

What Was Measured

PubMed files the paper under topics including Blood Transfusion, Cesarean Section, Hysterectomy, Placenta, Postpartum Hemorrhage, Postpartum Period and Vasopressins.

The authors tagged it with the keywords abnormally invasive placenta.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vasopressin.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2021 (International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics), a journal based in United States.

More context: the Vasopressin compound page, all human trials.